Animal health company Zoetis Inc. will enlarge its Lincoln, Neb., pharmaceutical plant to accommodate the transfer of products from a third-party manufacturer. A 19,000-square-foot, three-story expansion of Zoetis' Lincoln, Neb., plant could add 30 jobs. The 19,000-square-foot, three-story expansion could add 30 jobs to what is now a 500-employee operation. A groundbreaking is planned for this summer, with completion sometime in 2014, the company added. Operating since 1961, the Lincoln plant is one of 29 Zoetis manufacturing sites. It produces some of the company’s flagship products, including Bovi-Shield Gold cattle vaccine, RespiSure One swine medication and the anti-inflammatory canine drug Rimadyl. "This expansion shows our continuing commitment to the Lincoln community, a community that we have been a part of for several decades,” said Michael Morgan, site leader in Lincoln. Zoetis, headquartered in Madison, N.J., split from one-time parent company Pfizer Inc. in February and became fully independent as of June 24. In other news, Michael McCallister was appointed nonexecutive chairman of the Zoetis board of directors. McCallister, former CEO of the Humana health insurance company, replaces Frank D’Amelio, Pfizer’s CFO and executive vice president of business operations. The breakaway from Pfizer also led to the resignation of Pfizer executives Geno Germano, Douglas Giordano, Charles Hill and Amy Schulman from the Zoetis board. Added to the board as independent directors were Sanjay Khosla and Robert Scully. The changes to our board reflect our full independence from Pfizer and add valuable new experience to our leadership,” said Zoetis CEO Juan Ramón Alaix. <HOME>
